The Jefferies Group LLC Analysts Give Novartis AG (NOVN) a CHF 100 Price Target

The Jefferies Group LLC Analysts Give Novartis AG (NOVN) a CHF 100 Price Target

NOVN has been the topic of several other reports. JPMorgan Chase & Co. set a CHF 70 target price on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Goldman Sachs Group Inc set a CHF 80 target price on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Morgan Stanley set a CHF 75 target price on shares of Novartis AG and gave the stock a “sell” rating in a research note on Saturday, May 20th. Finally, Barclays PLC set a CHF 65 target price on shares of Novartis AG and gave the stock a “sell” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of CHF 78.

Novartis AG (VTX:NOVN) received a CHF 100 price objective from equities researchers at Jefferies Group LLC in a research report issued on Monday. The firm presently has a “buy” rating on the stock.

Novartis AG (NOVN) opened at 79.40 on Monday. The stock’s 50 day moving average is CHK 77.44 and its 200-day moving average is CHK 74.52. Novartis AG has a 12 month low of CHK 67.40 and a 12 month high of CHK 82.80.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Related posts

Leave a Comment